Impacting the research, diagnosis and treatment of human diseases through our novel antibody discovery and optimization platform.
Founded in 2010 by a team of experienced and successful life scientists and industry experts, Abzyme Therapeutics is a leading provider of recombinant antibody development, modification and production services. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia.
The company is founded on the scientific understanding of hypermutation in yeast, our experience in yeast biology and immunology. In immunized animals, somatic hypermutation plays a leading role in antibody maturation by generating point mutations in the V genes, which provides high-affinity antibodies required for the affinity maturation process. To bring revolutionary speed and diversity to antibody generation, Abzyme Therapeutics LLC developed yeast-based technology platforms mimicking mammalian antibody diversification and affinity maturation processes. As this is an animal-free in vitro system, we are able to develop antibodies not only to conventional targets but also to a variety of difficult targets including non-immunogenic and highly toxic antigens or cell surface antigens.
Unique to Abzyme is our proprietary eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody maturation, and a FACS single cell sorting approach to identify desired antibodies. These combined technologies enable Abzyme Therapeutics to shorten typical monoclonal antibody development/optimization times from 4.5 – 6 months to 6 – 10 weeks. Abzyme’s antibody discovery platform incorporates the ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity into real-time screening.
Abzyme Therapeutics provides comprehensive custom recombinant antibody discovery and development platform services. Our service offerings include antigen and project design, antibody discovery, antibody optimization, antibody production, and SPR-based antibody characterization. Our Recombinant Antibody Development programs comprise single domain camelid (VHH) and human (VH) antibodies, human ScFv and IgG antibodies and rabbit monoclonal antibodies. Abzyme offers endotoxin-free antibody production services for recombinant antibodies using bacterial expression systems as well as mammalian expression for customers concerned about glycosylation. Production scales from 250 ml to 100 L are within our standard capabilities.